Xenon Pharmaceuticals Inc.

Zalicus Pharmaceuticals, Ltd.

Nagasree Chakka

Shaoyi Sun

Shifeng Liu

Serguei Sviridov

Rajender Kamboj

Jianmin Fu

Sultan Chowdhury

Vishnumurthy Kodumuru

Duanjie Hou

Mikhail A Chafeev

Vandna Raina

Zaihui Zhang

Jianyu Sun

Tom Hsieh

Melwyn A Abreo

Michael D Winther

Heinz W Gschwend

Wenbao Li

Alla Yurevna Zenova

Qi Jia

Mark Wood

Simon James Gauthier

Jean-Jacques Alexandre Cadieux

Jonathan David Langille

Mehran Seid Bagherzadeh

Lauren Fraser

Robert Fraser

Zoran Cikojevic

Amy Frances Douglas

Yuanxi Zhou

Jian-Min Fu

Mark W Holladay

Hassan Pajouhesh

Yongbao Zhu

Yanbing Ding

Chi Tu

Ramesh Kaul

Daniel F Harvey

Mikhail Kondratenko

Lingyun Zhang

Sengen Sun

Jason Tan

Kashinath Sadalapure

Mike Grimwood

Michael Edward Grimwood

Mehran Bagherzadeh

Cindy J Hudson

Shifeng Lui

Mikhail A Kondratenko

Jian-min Fu

Kashinath Sadalupure

Sun Shaoyi

Michael Winther

Heinz Gschwend

This invention is directed to spiro-oxindole compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.

Spiro-oxindole compounds and their use as therapeutic agents

Methods and compounds effective in ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted T-type calcium channel activity are disclosed. Specifically, a series of compounds containing N-piperidinyl acetamide derivatives as shown in formula (1). 

N-piperidinyl acetamide derivatives as calcium channel blockers

This invention is directed to methods of using spiro-oxindole compounds of formula (I): wherein k, j, Q, R, R, R, R, R, R, R, R, and Rare as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, for the treatment and/or prevention of hypercholesterolemia, benign prostatic hyperplasia, pruritis and cancer. 

Use of spiro-oxindole compounds as therapeutic agents

Spiro-oxindole compounds and their uses as therapeutic agents

Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I): 

Pyridyl derivatives and their use as therapeutic agents

This invention is directed to spiro-oxindole compounds of formula (I): wherein k, j, Q, RR, R, R, R, R, R, R, and Rare as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, which are useful for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain. Pharmaceutical compositions comprising the compounds and methods of preparing and using the compounds are also disclosed.

Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I): where x, y, G, J, K, L, M, W, R, R, R, R, R, R, R, R, Rand Rare defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed.

Substituted pyridazines as stearoyl-CoA desaturase inhibitors

Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I): Formula (I) where x, y, G, J, L, M, V, W, R, R, R, R, R, R, R, R, R, R, and Rare defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed.

Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase

This invention is directed to the use of SCD-1 inhibitors of the formula (I): where x, y, V, W, G, J, L, M, R2, R3, R5, R5a, R6, R6a, R7, R7a, R8 and R8a are defined herein, in combination with other drug therapies to treat adverse weight gain. 

Combination therapy

Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I): where x, y, G, J, K, L, M, W, V, R, R, R, R, R, R, R, R, Rand Rare defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed. 

Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-CoA desaturase enzymes

Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors

Growing community of inventors

Burnaby, Canada

Nagasree Chakka